Observational studySurgical endoscopy2026
Colonic resection or self-expanding metal stents for obstructive left colon cancer: results of a national multicenter prospective cohort study (CROSCO-1).
Observational study in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05801211 (Colonic Resection, stOma, or Self-expandable Metallic Stent for obstruCtive Left cOlon Cancer. The CROSCO-1 Multicenter, Prospective Cohort Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Colonic Resection, stOma, or Self-expandable Metallic Stent for obstruCtive Left cOlon Cancer. The CROSCO-1 Multicenter, Prospective Cohort Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal management of acute left-sided malignant colonic obstruction remains controversial. Emergency surgery (ES) is associated with substantial morbidity and high stoma rates, whereas self-expanding metal stents (SEMS) as a bridge to surgery (BtS) may convert an emergency into an elective setting. This study aimed to compare the safety, efficacy, and quality-of-life outcomes of ES versus SEMS/BtS.
methodsCROSCO-1 is a national, multicenter, prospective observational cohort study conducted in Italy (ClinicalTrials.gov NCT05801211). Consecutive adults with obstructive, non-metastatic left-sided colon cancer (June 2023-October 2024) were included. Patients underwent ES or SEMS followed by elective resection. The primary endpoint was 1-year stoma rate. Secondary outcomes included morbidity, mortality, length of stay, time to chemotherapy, readmissions, oncologic outcomes, and 1-year quality of life (EQ-5D-5L).
resultsA total of 216 patients were analyzed (ES 144; SEMS/BtS 72). One-year follow-up for the primary outcome was available for 134 ESG and 70 SEMS/BtS patients. SEMS failure occurred in 8.3%. Major morbidity and mortality at 30 and 90 days were similar. The 1-year stoma rate was significantly lower after SEMS/BtS (44.4 vs 73.4%). SEMS/BtS reduced the risk of stoma persistence (adjusted OR 3.74 for ES; p = 0.016). SEMS/BtS was associated with fewer 30-day readmissions (4.2 vs 15.9%) and earlier chemotherapy initiation (76.1 vs 55.8%; p = 0.003). One-year oncologic outcomes were comparable, although limited by short follow-up. Quality of life was significantly better in the SEMS/BtS group.
conclusionsIn selected patients, SEMS as a bridge to surgery is associated with lower 1-year stoma rates and improved quality of life without increasing short-term morbidity. These findings support a tailored, multidisciplinary approach in experienced centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.